Description
This guidance provides a framework to facilitate the management of postapproval chemistry, manufacturing, and controls (CMC) changes in a more predictable and efficient manner. A harmonized approach regarding technical and regulatory considerations for lifecycle management will benefit patients, industry, and regulatory authorities by promoting innovation and continual improvement in the pharmaceutical sector, strengthening quality assurance, and improving supply of medicinal products.
Key Topics
Terms and concepts identified from this document
Scope & Applicability
Product Classes
3Products combining drug, device, or biological constituents; Generally recommended for Enhanced Documentation; Requires 14971-based framework incorporating ICH Q9; A drug-device combination where the device constituent part detects ingestion.
Regulated under section 351(i) of the PHS Act; Virus, therapeutic serum, toxin, vaccine, or protein applicable to prevention or treatment; Alternative regulation category for products meeting device definition
Products for which ECs must be defined for device elements.
Stakeholders
5Early discussion is recommended regarding safety dataset size.; Entities with whom the adequacy of RWD and extrapolation plans should be discussed.; early discussion useful when proposed endpoints differ; Entities that should agree upon success criteria in advance.
Oversees reprocess or rework of batches
Stakeholders involved in change control process
Entity responsible for managing the submission of PBRERs
Marketing Authorization Holder responsible for safety reporting; Marketing Authorization Holder responsible for providing exposure data; Marketing Authorization Holder responsible for signal evaluation and reporting.; Marketing Authorization Holder responsible for presenting efficacy information
Regulatory Context
Regulatory Activities
6Marketing Authorization Application referenced for submission of ECs and PACMPs.
FDA verification of qualified facility status, including for-cause inspections
Post-Approval Change Management Protocol examples; Postapproval Change Management Protocol; Post-Approval Change Management Protocol for site transfers and process changes
Submission for product approval
Regulatory tool providing predictability for future CMC changes
Submissions supported by clinical trial data.
Document Types
10PACMP used as a tool for life cycle management
Written agreements with suppliers of goods and services to ensure compliance with CGMP.
ensures that the change is included and assessed as part of the PQR
Product Lifecycle Management document outlines the specific plan for product lifecycle management.
Location where the PACMP document can be located.; The PLCM document can be located in CTD Module 3.2.R.
Referenced submission in an MAA.
OPQ reviews controlled correspondence inquiries related to Type II drug master files
Document outlining ECs and reporting categories; PLCM document included in eCTD section 3.2.R; Document including proposed ECs and reporting categories; Appendix C example of a PLM document
Format for submitting development information; Module 3 of the CTD for detailed descriptions of analytical procedures; ICH guideline M4Q(R1) for the registration of pharmaceuticals.
Submissions to the MAA regarding postapproval changes
Attributes
5Classification of CMC changes based on risk to product quality; Classification for making changes to approved ECs.
The degree of uncertainty can impact the critical quality attribute (CQA) risk ranking
CPPs that can influence CQAs
Determined based on stability data; Established through stability testing; also called dating period.; Established through formal stability studies; Establishing the period during which a drug product is expected to remain within specifications; Period for drug products; The period during which a drug product is expected to remain within specifications; Duration product remains within acceptance criteria; Period during which product remains within specifications; Established for intermediates pu
Process inputs used to describe the design space.; measured material attributes used in real time release testing
Technical Details
Substances
3Postapproval changes to drug substances; the active pharmaceutical ingredient being modified; Evaluation of physical properties for drug substance; Active ingredient intended to furnish pharmacological activity; The molecule or ion responsible for the physiological or pharmacological action.; The active pharmaceutical ingredient subject to postapproval changes
Component used in human and animal drugs
Finished dosage form undergoing stability testing
Testing Methods
8Used to support the evaluation of CMC changes
The analytical procedure refers to the way of performing the analysis.
Long-term, accelerated, and forced degradation studies to ensure shelf life.; studies to be performed to demonstrate suitability
Tests performed to evaluate the potential impact of proposed changes.
Tests performed to evaluate the potential impact of proposed changes.
Used to enable timely implementation of CMC changes
Used to examine samples for physical, chemical or biological changes
PAT is used to monitor conversion and measure impurities.
Processes
4Categorization of postapproval Chemistry, Manufacturing, and Controls changes
Steps to be completed before implementation of a change.
Development program considerations for EUA
Changes to this process may affect the identity and NDI status of an ingredient.; Changes to this process may create an NDI; you should describe the manufacturing process and provide detailed information; includes fermentation as an intrinsic part of identity
Standards & References
External Standards
1Changes to comply with new monographs are out of scope
Specifications
2Part of the control strategy to assure product quality.
Metrics established by developers for each test element.
ICH References (10)
Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management; referenced for established conditions and life cycle management tools; in line with recommendations described in ICH Q12; Guideline for technical and regulatory considerations for pharmaceutical product lifecycle management; Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management.
Principles of Quality by Design described within ICH Q8-Q11.; Pharmaceutical development guidance; Pharmaceutical development and CQA measurement during processing; Defines product lifecycle phases; Referenced for Critical Quality Attributes (CQA); Pharmaceutical Development.; General principles related to model development, validation and verification; Principles described in ICH Q8 apply to stability models; Pharmaceutical Development guideline mentioned regarding enhanced level of understandi
Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process
Validation of Analytical Procedures: Text and Methodology
Organization of the Common Technical Document; Organization of the Common Technical Document for the Registration of Pharmaceuticals for Human Use
Stability Testing of New Drug Substances and Products
Pharmaceutical Development
Quality Risk Management recommended for combination products
Pharmaceutical Quality System
Development and Manufacture of Drug Substances; General principles for selection of starting materials
Related CFR Sections (3)
- 21CFR601.12§ 601.12 Changes to an approved application.
(a) General.Read full regulation →
- 21CFR314.70§ 314.70 Supplements and other changes to an approved NDA.
(a) Changes to an approved NDA.Read full regulation →
- 21CFR314.420§ 314.420 Drug master files.
(a) A drug master file is a submission of information to the Food and Drug Administration by a person (the drug master file holder) who intends it to be used for one of the following purposes: To permit the holder to incorporate the information by reference when the holder submits an investigationalRead full regulation →
Enforcement Impact
Deficiencies cited in Warning Letters referencing the same regulations
Recent Cases
- 2026-02-24
CGMP/Finished Pharmaceuticals/Adulterated
AQ USA Inc., d.b.a Ross Healthcare Inc.
- 2026-02-24
Compounding Pharmacy/Adulterated Drug Products
MedisourceRx
- 2026-02-24
CGMP/Finished Pharmaceuticals/Adulterated
A. Nelson & Co. Ltd.
- 2026-02-17
CGMP/Finished Pharmaceuticals/Adulterated
Cosmetic Manufacturers Pty Ltd.
- 2025-12-23
CGMP/Finished Pharmaceuticals/Adulterated
SV Labs Corporation
Related Warning Letters (10)
- 2026-02-24
CGMP/Finished Pharmaceuticals/Adulterated
AQ USA Inc., d.b.a Ross Healthcare Inc.
- 2026-02-24
Compounding Pharmacy/Adulterated Drug Products
MedisourceRx
- 2026-02-24
CGMP/Finished Pharmaceuticals/Adulterated
A. Nelson & Co. Ltd.
- 2026-02-17
CGMP/Finished Pharmaceuticals/Adulterated
Cosmetic Manufacturers Pty Ltd.
- 2025-12-23
CGMP/Finished Pharmaceuticals/Adulterated
SV Labs Corporation
- 2025-12-23
CGMP/Finished Pharmaceuticals/Adulterated
Guangdong Renhe Guozhuang Biotechnology Co., Ltd.
- 2025-12-23
CGMP/Finished Pharmaceuticals/Adulterated
Medinatura New Mexico, Inc.
- 2025-12-16
CGMP/Finished Pharmaceuticals/Adulterated
Sklar Personal Care Inc.
- 2025-12-16
CGMP/Deviations/Biologics License Application (BLA)
Microvascular Tissue, Inc.
- 2025-12-11
CGMP/Finished Pharmaceuticals/Adulterated
Catalent Indiana, LLC
Related MFDS Guidelines
Korean regulatory guidelines covering similar topics
See Also (8)
- Alternative Tools: Assessing Drug Manufacturing Facilities Identified in Pending Applications (Status: Final)
- CPG Sec. 460.100 Hospital Pharmacies - Status as Drug Manufacturer (Status: Final)
- CPG Sec. 430.200 Repacking of Drug Products - Testing/Examination under CGMPs (Status: Final)
- CPG Sec. 425.300 Computerized Drug Processing; Source Code for Process Control Application Programs (Status: Final)
- CPG Sec. 410.100 *Finished Dosage Form Drug Products in Bulk Containers - Applications of Current Good Manufacturing Practice Regulations* (Status: Final)
- CPG Sec. 480.100 Requirements for Expiration Dating and Stability Testing (Status: Final)
- CPG Sec. 130.400 Use of Microfiche and/or Microfilm for Method of Records Retention (Status: Final)
- CPG Sec. 400.210, Radiofrequency Identification Feasibility Studies and Pilot Programs for Drugs (Status: Final)